<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564120</url>
  </required_header>
  <id_info>
    <org_study_id>UNC-10-1483</org_study_id>
    <nct_id>NCT02564120</nct_id>
  </id_info>
  <brief_title>North Carolina Prostate Cancer Comparative Effectiveness &amp; Survivorship Study (NC ProCESS)</brief_title>
  <official_title>North Carolina Prostate Cancer Comparative Effectiveness &amp; Survivorship Study (NC ProCESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NC ProCESS is a cohort of patients from diverse backgrounds diagnosed with early prostate
      cancer, who were enrolled from January 2011-June 2013. These patients were recruited
      throughout North Carolina, and also in partnership with institutions across the country.
      Patients enrolled before they start treatment, and are then followed prospectively through
      treatment and then afterwards. This observational study collects information on quality of
      life, cancer control, and health care received inclusive of treatment and management of
      subsequent effects including complications and recurrence. The objective of this study is to
      examine comparative outcomes among different modern prostate cancer treatment options in this
      cohort of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Localized prostate cancer treatment options is consistently a &quot;highest priority&quot; comparative
      effectiveness research (CER) topic according to the Institute of Medicine, Agency for
      Healthcare Research and Quality (AHRQ), and other summary reports. Patients urgently need
      information on the comparative outcomes of modern treatment options to guide decision-making
      for this disease that causes significant burden based on its high prevalence, mortality and
      treatment effects on quality of life. The status quo as it pertains to prostate cancer is
      significant overtreatment causing potential patient harm, rapid diffusion of new/expensive
      technologies without proven benefit and patients lacking high quality research evidence to
      balance direct-to-consumer advertising and guide individualized decision-making.

      NC ProCESS is a population-based cohort designed specifically to address well-described
      knowledge gaps. It was designed in close collaboration with the unique AHRQ consortium
      stakeholder group, which included representatives from patients, clinicians and policymakers.
      Stakeholders helped define study design to emphasize &quot;real-world&quot; patients and select
      patient-centered and relevant outcomes, and have been involved throughout assembly of this
      patient cohort. The diverse cohort is well-represented by &quot;hard to reach&quot; patients;
      enrollment before treatment avoids biases with participation and recall. As clinical trials
      are not feasible to address the central questions in prostate cancer CER, this prospective
      study will yield the highest level of evidence to inform patients and other stakeholders.
      With an assembled cohort, this study is necessary to examine comparative outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cancer-specific Quality of Life</measure>
    <time_frame>4 years</time_frame>
    <description>Prostate Cancer Symptom Indices (PCSI) - measures treatment-related morbidity and adverse effects and is comprised of 4 functional scales measuring Sexual Dysfunction, Bowel Problems, Urinary Incontinence, and Urinary Obstruction/Irritation. Four parallel distress indices measure distress from symptoms. In each index, patient answers are converted to a score from 0 (no symptom/distress) to 100 (maximum symptoms/distress). A 5-10 point difference in QOL is considered &quot;clinically meaningful.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Quality of Life</measure>
    <time_frame>4 years</time_frame>
    <description>Short Form-12 (SF12) - Measures health-related quality of life. Consists of Likert response formats that assess overall health, mental health, vitality, social functioning, and whether ones health or pain limits their daily physical activities. The SF-12 also contains four categorical questions (yes or no) that assess limitations in functioning due to physical and emotional health. The SF-12 provides the Mental Component Summary score (MCS) and Physical Component Summary score (PCS), calculated using norm-based scoring, with the mean set at 50 and standard deviation 10. A lower score indicates lower QOL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prostate Cancer Recurrence</measure>
    <time_frame>From date of completion of treatment (radiation or surgery) until the date of recurrence or date of death from any cause, whichever came first, assessed up to 5 years.</time_frame>
    <description>Percentage of patients who had a recurrence of prostate cancer during 5 years of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate Cancer Anxiety</measure>
    <time_frame>4 years</time_frame>
    <description>Prostate cancer anxiety was measured by the validated Memorial Anxiety Scale for Prostate Cancer (MAX-PC), with 18 questions assessing anxiety related to prostate cancer (11 items, total score 0 to 33), PSA testing (3 items, total score 0 to 9), and fear of recurrence (4 items, total score 0 to 12). The subscale for prostate cancer anxiety asks the patient to report how frequently comments about prostate cancer were true for them during the past week (not at all, rarely, sometimes, or often). The subscale for PSA testing anxiety asks the patient to indicate how frequently situations have ever been true for them. The subscale for anxiety related to prostate cancer recurrence asks the patient to indicate how much they agree or disagree with statements about their own health during the past week. A higher score in each subscale indicates more anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decisional Regret</measure>
    <time_frame>4 years</time_frame>
    <description>Decisional regret was measured by a validated scale for prostate cancer. The five items of the decisional regret scale assess (on a Likert scale) a patient's feeling that he chose the wrong treatment, a wish to change the decision, or doubt about treatment value.
Answers are converted to a score from 0 (no regret) to 100 (maximum regret). Decisional regret provides an assessment of the overall decisional and treatment experience from a patient perspective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year Mortality</measure>
    <time_frame>From date of diagnosis until date of death or end of follow-up up to 5 years</time_frame>
    <description>Percentage of patients who died within 5 years of follow-up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Physician Visits During Follow-up</measure>
    <time_frame>4 years</time_frame>
    <description>Number of physician and specialist visits during treatment, subsequent monitoring of recurrence and management of prostate cancer treatment-related morbidity. Assessed through analysis of healthcare claims linked to cohort data.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Diagnostic Tests and Procedures During Follow-up</measure>
    <time_frame>4 years</time_frame>
    <description>Number of diagnostic tests and procedures including biopsies, radiographic scans, laboratory tests, and procedures to assess cancer progression (active surveillance) or recurrence and work-up for treatment-related morbidity. Assessed through analysis of healthcare claims linked to cohort data.</description>
  </other_outcome>
  <enrollment type="Actual">1556</enrollment>
  <condition>Cancer of Prostate</condition>
  <condition>Cancer of the Prostate</condition>
  <condition>Prostate Cancer</condition>
  <condition>Prostatic Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Newly-diagnosed, early stage (localized, non-metastatic) prostate cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly-diagnosed, histologically-proven, localized prostate adenocarcinoma.

          -  Completion of baseline interview prior to initiating therapy.

          -  Patient ability to complete study interview: no cognitive impairment, language or
             hearing problems.

          -  Not diagnosed with prostate cancer through transurethral resection of the prostate
             (TURP).

          -  Age 35-80.

          -  English speaking.

          -  Has telephone.

        Exclusion Criteria:

          -  Initiation of treatment for prostate cancer prior to completion of baseline interview.

          -  Cognitive impairment.

          -  Hearing problems.

          -  Inability to speak or understand English.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <results_first_submitted>May 7, 2019</results_first_submitted>
  <results_first_submitted_qc>March 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2020</results_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02564120/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NC ProCESS Cohort</title>
          <description>NC ProCESS is a cohort of patients with early prostate cancer, who were enrolled from January 2011-June 2013. These patients were recruited throughout North Carolina, and also in partnership with institutions across the country. Patients enrolled before they started treatment, and were then followed prospectively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1556"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="446"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not return release forms</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other medical condition</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analytic cohort comprised 1413 men who completed baseline survey information and either underwent active surveillance (n=390, 27.6%) or received treatment with SBRT (n=104, 7.4%), radical prostatectomy (n=547, 38.7%), conventional fractionation external beam radiation therapy (EBRT; n=247, 17.5%), or brachytherapy (n=125, 8.8%).</population>
      <group_list>
        <group group_id="B1">
          <title>Active Surveillance</title>
          <description>Men placed on active surveillance (i.e., did not receive immediate treatment)</description>
        </group>
        <group group_id="B2">
          <title>SBRT</title>
          <description>Men who received stereotactic body radiation therapy</description>
        </group>
        <group group_id="B3">
          <title>Radical Prostatectomy</title>
          <description>Men treated with radical prostatectomy (i.e., surgery)</description>
        </group>
        <group group_id="B4">
          <title>EBRT</title>
          <description>Men treated with external beam radiation therapy</description>
        </group>
        <group group_id="B5">
          <title>Brachytherapy</title>
          <description>Men treated with brachytherapy</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="390"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="547"/>
            <count group_id="B4" value="247"/>
            <count group_id="B5" value="125"/>
            <count group_id="B6" value="1413"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="7.5"/>
                    <measurement group_id="B2" value="65.3" spread="6.8"/>
                    <measurement group_id="B3" value="61.1" spread="7.0"/>
                    <measurement group_id="B4" value="66.8" spread="7.1"/>
                    <measurement group_id="B5" value="64.6" spread="7.3"/>
                    <measurement group_id="B6" value="64.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="547"/>
                    <measurement group_id="B4" value="247"/>
                    <measurement group_id="B5" value="125"/>
                    <measurement group_id="B6" value="1413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="382"/>
                    <measurement group_id="B4" value="153"/>
                    <measurement group_id="B5" value="90"/>
                    <measurement group_id="B6" value="1009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="143"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="547"/>
                    <measurement group_id="B4" value="247"/>
                    <measurement group_id="B5" value="125"/>
                    <measurement group_id="B6" value="1413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cancer-specific Quality of Life</title>
        <description>Prostate Cancer Symptom Indices (PCSI) - measures treatment-related morbidity and adverse effects and is comprised of 4 functional scales measuring Sexual Dysfunction, Bowel Problems, Urinary Incontinence, and Urinary Obstruction/Irritation. Four parallel distress indices measure distress from symptoms. In each index, patient answers are converted to a score from 0 (no symptom/distress) to 100 (maximum symptoms/distress). A 5-10 point difference in QOL is considered &quot;clinically meaningful.&quot;</description>
        <time_frame>4 years</time_frame>
        <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Surveillance</title>
            <description>Patients placed on active surveillance following diagnosis of prostate cancer. Active surveillance was defined with medical records stating this as the plan.</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Body Radiation Therapy</title>
            <description>Patients who received initial treatment with stereotactic body radiation therapy (SBRT).</description>
          </group>
          <group group_id="O3">
            <title>Radical Prostatectomy</title>
            <description>Patients who received initial treatment with radical prostatectomy.</description>
          </group>
          <group group_id="O4">
            <title>External Body Radiation Therapy</title>
            <description>Patients who received initial treatment with external body radiation therapy (EBRT).</description>
          </group>
          <group group_id="O5">
            <title>Brachytherapy</title>
            <description>Patients who received initial treatment with brachytherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Cancer-specific Quality of Life</title>
          <description>Prostate Cancer Symptom Indices (PCSI) - measures treatment-related morbidity and adverse effects and is comprised of 4 functional scales measuring Sexual Dysfunction, Bowel Problems, Urinary Incontinence, and Urinary Obstruction/Irritation. Four parallel distress indices measure distress from symptoms. In each index, patient answers are converted to a score from 0 (no symptom/distress) to 100 (maximum symptoms/distress). A 5-10 point difference in QOL is considered &quot;clinically meaningful.&quot;</description>
          <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="547"/>
                <count group_id="O4" value="247"/>
                <count group_id="O5" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sexual Dysfunction - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="547"/>
                    <count group_id="O4" value="247"/>
                    <count group_id="O5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="40.9" upper_limit="48.5"/>
                    <measurement group_id="O2" value="42.0" lower_limit="34.7" upper_limit="49.3"/>
                    <measurement group_id="O3" value="35.9" lower_limit="32.8" upper_limit="39.0"/>
                    <measurement group_id="O4" value="52.1" lower_limit="47.2" upper_limit="57.0"/>
                    <measurement group_id="O5" value="44.9" lower_limit="38.0" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Dysfunction - 3-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="445"/>
                    <count group_id="O4" value="224"/>
                    <count group_id="O5" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="40.0" upper_limit="48.8"/>
                    <measurement group_id="O2" value="42.1" lower_limit="34.7" upper_limit="49.5"/>
                    <measurement group_id="O3" value="78.0" lower_limit="75.5" upper_limit="80.5"/>
                    <measurement group_id="O4" value="65.2" lower_limit="60.3" upper_limit="70.1"/>
                    <measurement group_id="O5" value="59.0" lower_limit="52.3" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Dysfunction - 12-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" lower_limit="43.8" upper_limit="52.6"/>
                    <measurement group_id="O2" value="48.2" lower_limit="40.7" upper_limit="55.7"/>
                    <measurement group_id="O3" value="70.8" lower_limit="67.9" upper_limit="73.7"/>
                    <measurement group_id="O4" value="62.8" lower_limit="57.8" upper_limit="67.8"/>
                    <measurement group_id="O5" value="59.3" lower_limit="52.3" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Dysfunction - 24-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="381"/>
                    <count group_id="O4" value="181"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" lower_limit="50.4" upper_limit="60.0"/>
                    <measurement group_id="O2" value="48.8" lower_limit="40.8" upper_limit="56.8"/>
                    <measurement group_id="O3" value="68.2" lower_limit="65.0" upper_limit="71.4"/>
                    <measurement group_id="O4" value="64.9" lower_limit="59.7" upper_limit="70.1"/>
                    <measurement group_id="O5" value="62.3" lower_limit="54.7" upper_limit="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Dysfunction - 36-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="330"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" lower_limit="45.8" upper_limit="56.0"/>
                    <measurement group_id="O2" value="52.3" lower_limit="43.7" upper_limit="60.9"/>
                    <measurement group_id="O3" value="68.6" lower_limit="65.1" upper_limit="72.1"/>
                    <measurement group_id="O4" value="64.2" lower_limit="58.5" upper_limit="69.9"/>
                    <measurement group_id="O5" value="63.7" lower_limit="55.9" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Dysfunction - 48-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="302"/>
                    <count group_id="O4" value="141"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" lower_limit="51.1" upper_limit="61.9"/>
                    <measurement group_id="O2" value="53.9" lower_limit="44.0" upper_limit="63.8"/>
                    <measurement group_id="O3" value="69.7" lower_limit="66.0" upper_limit="73.4"/>
                    <measurement group_id="O4" value="66.1" lower_limit="60.4" upper_limit="71.8"/>
                    <measurement group_id="O5" value="64.0" lower_limit="55.7" upper_limit="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Obstruction &amp; Irritation - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="547"/>
                    <count group_id="O4" value="247"/>
                    <count group_id="O5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" lower_limit="22.0" upper_limit="24.8"/>
                    <measurement group_id="O2" value="22.9" lower_limit="20.4" upper_limit="25.4"/>
                    <measurement group_id="O3" value="23.3" lower_limit="22.1" upper_limit="24.5"/>
                    <measurement group_id="O4" value="24.2" lower_limit="22.2" upper_limit="26.2"/>
                    <measurement group_id="O5" value="17.5" lower_limit="15.7" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Obstruction &amp; Irritation - 3-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="445"/>
                    <count group_id="O4" value="224"/>
                    <count group_id="O5" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="21.7" upper_limit="24.7"/>
                    <measurement group_id="O2" value="24.3" lower_limit="21.7" upper_limit="26.9"/>
                    <measurement group_id="O3" value="27.0" lower_limit="25.5" upper_limit="28.5"/>
                    <measurement group_id="O4" value="35.6" lower_limit="33.0" upper_limit="38.2"/>
                    <measurement group_id="O5" value="40.3" lower_limit="36.3" upper_limit="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Obstruction &amp; Irritation - 12-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" lower_limit="24.1" upper_limit="27.7"/>
                    <measurement group_id="O2" value="29.5" lower_limit="26.2" upper_limit="32.8"/>
                    <measurement group_id="O3" value="21.4" lower_limit="20.1" upper_limit="22.7"/>
                    <measurement group_id="O4" value="25.3" lower_limit="23.2" upper_limit="27.4"/>
                    <measurement group_id="O5" value="27.6" lower_limit="24.3" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Obstruction &amp; Irritation - 24-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="381"/>
                    <count group_id="O4" value="181"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" lower_limit="23.3" upper_limit="26.9"/>
                    <measurement group_id="O2" value="26.4" lower_limit="23.3" upper_limit="29.5"/>
                    <measurement group_id="O3" value="19.4" lower_limit="18.1" upper_limit="20.7"/>
                    <measurement group_id="O4" value="23.7" lower_limit="21.6" upper_limit="25.8"/>
                    <measurement group_id="O5" value="26.9" lower_limit="23.5" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Obstruction &amp; Irritation - 36-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="330"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="21.9" upper_limit="25.5"/>
                    <measurement group_id="O2" value="22.8" lower_limit="19.6" upper_limit="26.0"/>
                    <measurement group_id="O3" value="19.5" lower_limit="18.2" upper_limit="20.8"/>
                    <measurement group_id="O4" value="22.5" lower_limit="20.3" upper_limit="24.7"/>
                    <measurement group_id="O5" value="19.5" lower_limit="16.7" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Obstruction &amp; Irritation - 48-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="302"/>
                    <count group_id="O4" value="141"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" lower_limit="22.3" upper_limit="26.3"/>
                    <measurement group_id="O2" value="22.9" lower_limit="19.9" upper_limit="25.9"/>
                    <measurement group_id="O3" value="19.2" lower_limit="17.9" upper_limit="20.5"/>
                    <measurement group_id="O4" value="23.8" lower_limit="21.5" upper_limit="26.1"/>
                    <measurement group_id="O5" value="22.2" lower_limit="19.0" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Incontinence - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="547"/>
                    <count group_id="O4" value="247"/>
                    <count group_id="O5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="8.9" upper_limit="13.1"/>
                    <measurement group_id="O2" value="8.3" lower_limit="5.2" upper_limit="11.4"/>
                    <measurement group_id="O3" value="8.6" lower_limit="7.1" upper_limit="10.1"/>
                    <measurement group_id="O4" value="14.1" lower_limit="11.2" upper_limit="17.0"/>
                    <measurement group_id="O5" value="6.0" lower_limit="3.4" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Incontinence - 3-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="445"/>
                    <count group_id="O4" value="224"/>
                    <count group_id="O5" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="9.9" upper_limit="14.7"/>
                    <measurement group_id="O2" value="12.7" lower_limit="9.1" upper_limit="16.3"/>
                    <measurement group_id="O3" value="44.0" lower_limit="41.3" upper_limit="46.7"/>
                    <measurement group_id="O4" value="17.6" lower_limit="14.2" upper_limit="21.0"/>
                    <measurement group_id="O5" value="15.1" lower_limit="11.0" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Incontinence - 12-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="11.4" upper_limit="16.6"/>
                    <measurement group_id="O2" value="15.2" lower_limit="10.9" upper_limit="19.5"/>
                    <measurement group_id="O3" value="31.5" lower_limit="29.0" upper_limit="34.0"/>
                    <measurement group_id="O4" value="18.7" lower_limit="15.0" upper_limit="22.4"/>
                    <measurement group_id="O5" value="13.9" lower_limit="9.9" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Incontinence -24-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="381"/>
                    <count group_id="O4" value="181"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="15.4" upper_limit="21.8"/>
                    <measurement group_id="O2" value="14.8" lower_limit="10.0" upper_limit="19.6"/>
                    <measurement group_id="O3" value="29.7" lower_limit="27.1" upper_limit="32.3"/>
                    <measurement group_id="O4" value="20.1" lower_limit="16.3" upper_limit="23.9"/>
                    <measurement group_id="O5" value="16.3" lower_limit="11.4" upper_limit="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Incontinence - 36-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="330"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" lower_limit="12.8" upper_limit="19.0"/>
                    <measurement group_id="O2" value="15.1" lower_limit="10.5" upper_limit="19.7"/>
                    <measurement group_id="O3" value="28.8" lower_limit="26.0" upper_limit="31.6"/>
                    <measurement group_id="O4" value="20.4" lower_limit="16.2" upper_limit="24.6"/>
                    <measurement group_id="O5" value="21.6" lower_limit="15.7" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary Incontinence - 48-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="302"/>
                    <count group_id="O4" value="141"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" lower_limit="16.5" upper_limit="23.3"/>
                    <measurement group_id="O2" value="11.5" lower_limit="6.8" upper_limit="16.2"/>
                    <measurement group_id="O3" value="30.8" lower_limit="28.0" upper_limit="33.6"/>
                    <measurement group_id="O4" value="19.9" lower_limit="15.6" upper_limit="24.2"/>
                    <measurement group_id="O5" value="16.5" lower_limit="11.4" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Problems - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="547"/>
                    <count group_id="O4" value="247"/>
                    <count group_id="O5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.3" upper_limit="6.9"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.2" upper_limit="6.8"/>
                    <measurement group_id="O3" value="5.8" lower_limit="5.1" upper_limit="6.5"/>
                    <measurement group_id="O4" value="7.5" lower_limit="6.2" upper_limit="8.8"/>
                    <measurement group_id="O5" value="4.8" lower_limit="3.5" upper_limit="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Problems - 3-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="445"/>
                    <count group_id="O4" value="224"/>
                    <count group_id="O5" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.0" upper_limit="8.2"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.3" upper_limit="6.9"/>
                    <measurement group_id="O3" value="7.1" lower_limit="6.3" upper_limit="7.9"/>
                    <measurement group_id="O4" value="12.6" lower_limit="10.5" upper_limit="14.7"/>
                    <measurement group_id="O5" value="9.0" lower_limit="7.1" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Problems - 12-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="5.9" upper_limit="8.3"/>
                    <measurement group_id="O2" value="5.9" lower_limit="4.4" upper_limit="7.4"/>
                    <measurement group_id="O3" value="6.2" lower_limit="5.4" upper_limit="7.0"/>
                    <measurement group_id="O4" value="9.4" lower_limit="7.7" upper_limit="11.1"/>
                    <measurement group_id="O5" value="7.2" lower_limit="5.6" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Problems - 24-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="381"/>
                    <count group_id="O4" value="181"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="5.3" upper_limit="7.1"/>
                    <measurement group_id="O2" value="5.0" lower_limit="3.8" upper_limit="6.2"/>
                    <measurement group_id="O3" value="5.6" lower_limit="4.8" upper_limit="6.4"/>
                    <measurement group_id="O4" value="9.5" lower_limit="7.5" upper_limit="11.5"/>
                    <measurement group_id="O5" value="6.1" lower_limit="4.6" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Problems - 36-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="330"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="5.8" upper_limit="8.0"/>
                    <measurement group_id="O2" value="5.9" lower_limit="4.6" upper_limit="7.2"/>
                    <measurement group_id="O3" value="5.6" lower_limit="4.7" upper_limit="6.5"/>
                    <measurement group_id="O4" value="8.4" lower_limit="6.5" upper_limit="10.3"/>
                    <measurement group_id="O5" value="5.8" lower_limit="3.8" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Problems - 48-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="302"/>
                    <count group_id="O4" value="141"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="5.7" upper_limit="8.5"/>
                    <measurement group_id="O2" value="4.4" lower_limit="2.7" upper_limit="6.1"/>
                    <measurement group_id="O3" value="5.3" lower_limit="4.4" upper_limit="6.2"/>
                    <measurement group_id="O4" value="7.1" lower_limit="5.6" upper_limit="8.6"/>
                    <measurement group_id="O5" value="7.4" lower_limit="5.2" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Quality of Life</title>
        <description>Short Form-12 (SF12) - Measures health-related quality of life. Consists of Likert response formats that assess overall health, mental health, vitality, social functioning, and whether ones health or pain limits their daily physical activities. The SF-12 also contains four categorical questions (yes or no) that assess limitations in functioning due to physical and emotional health. The SF-12 provides the Mental Component Summary score (MCS) and Physical Component Summary score (PCS), calculated using norm-based scoring, with the mean set at 50 and standard deviation 10. A lower score indicates lower QOL.</description>
        <time_frame>4 years</time_frame>
        <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Surveillance</title>
            <description>Patients placed on active surveillance following diagnosis of prostate cancer. Active surveillance was defined with medical records stating this as the plan.</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Body Radiation Therapy</title>
            <description>Patients who received initial treatment with stereotactic body radiation therapy (SBRT).</description>
          </group>
          <group group_id="O3">
            <title>Radical Prostatectomy</title>
            <description>Patients who received initial treatment with radical prostatectomy.</description>
          </group>
          <group group_id="O4">
            <title>External Body Radiation Therapy</title>
            <description>Patients who received initial treatment with external body radiation therapy (EBRT).</description>
          </group>
          <group group_id="O5">
            <title>Brachytherapy</title>
            <description>Patients who received initial treatment with brachytherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Quality of Life</title>
          <description>Short Form-12 (SF12) - Measures health-related quality of life. Consists of Likert response formats that assess overall health, mental health, vitality, social functioning, and whether ones health or pain limits their daily physical activities. The SF-12 also contains four categorical questions (yes or no) that assess limitations in functioning due to physical and emotional health. The SF-12 provides the Mental Component Summary score (MCS) and Physical Component Summary score (PCS), calculated using norm-based scoring, with the mean set at 50 and standard deviation 10. A lower score indicates lower QOL.</description>
          <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="547"/>
                <count group_id="O4" value="247"/>
                <count group_id="O5" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Health - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="547"/>
                    <count group_id="O4" value="247"/>
                    <count group_id="O5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.8" lower_limit="46.7" upper_limit="48.9"/>
                    <measurement group_id="O2" value="52.1" lower_limit="50.5" upper_limit="53.7"/>
                    <measurement group_id="O3" value="51.1" lower_limit="50.3" upper_limit="51.9"/>
                    <measurement group_id="O4" value="47.6" lower_limit="46.2" upper_limit="49.0"/>
                    <measurement group_id="O5" value="50.4" lower_limit="48.8" upper_limit="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health - 3-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="445"/>
                    <count group_id="O4" value="224"/>
                    <count group_id="O5" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="46.4" upper_limit="48.8"/>
                    <measurement group_id="O2" value="50.8" lower_limit="49.0" upper_limit="52.6"/>
                    <measurement group_id="O3" value="49.4" lower_limit="48.5" upper_limit="50.3"/>
                    <measurement group_id="O4" value="46.4" lower_limit="45.0" upper_limit="47.8"/>
                    <measurement group_id="O5" value="49.0" lower_limit="47.4" upper_limit="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health - 12-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" lower_limit="47.1" upper_limit="49.3"/>
                    <measurement group_id="O2" value="50.8" lower_limit="49.2" upper_limit="52.4"/>
                    <measurement group_id="O3" value="49.8" lower_limit="48.9" upper_limit="50.7"/>
                    <measurement group_id="O4" value="46.9" lower_limit="45.5" upper_limit="48.3"/>
                    <measurement group_id="O5" value="48.7" lower_limit="46.8" upper_limit="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health - 24-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="381"/>
                    <count group_id="O4" value="181"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" lower_limit="45.5" upper_limit="48.1"/>
                    <measurement group_id="O2" value="51.2" lower_limit="49.3" upper_limit="53.1"/>
                    <measurement group_id="O3" value="48.6" lower_limit="47.6" upper_limit="49.6"/>
                    <measurement group_id="O4" value="46.2" lower_limit="44.7" upper_limit="47.7"/>
                    <measurement group_id="O5" value="47.3" lower_limit="45.1" upper_limit="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health - 36-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="330"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.8" lower_limit="45.4" upper_limit="48.2"/>
                    <measurement group_id="O2" value="50.8" lower_limit="48.8" upper_limit="52.8"/>
                    <measurement group_id="O3" value="49.0" lower_limit="48.0" upper_limit="50.0"/>
                    <measurement group_id="O4" value="46.6" lower_limit="44.8" upper_limit="48.4"/>
                    <measurement group_id="O5" value="48.0" lower_limit="45.7" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Health - 48-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="302"/>
                    <count group_id="O4" value="141"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" lower_limit="44.7" upper_limit="47.5"/>
                    <measurement group_id="O2" value="50.7" lower_limit="48.5" upper_limit="52.9"/>
                    <measurement group_id="O3" value="48.4" lower_limit="47.3" upper_limit="49.5"/>
                    <measurement group_id="O4" value="45.9" lower_limit="44.2" upper_limit="47.6"/>
                    <measurement group_id="O5" value="45.8" lower_limit="43.3" upper_limit="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="390"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="547"/>
                    <count group_id="O4" value="247"/>
                    <count group_id="O5" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.6" lower_limit="53.8" upper_limit="55.4"/>
                    <measurement group_id="O2" value="53.2" lower_limit="51.7" upper_limit="54.7"/>
                    <measurement group_id="O3" value="52.0" lower_limit="51.2" upper_limit="52.8"/>
                    <measurement group_id="O4" value="52.9" lower_limit="51.7" upper_limit="54.1"/>
                    <measurement group_id="O5" value="54.8" lower_limit="53.3" upper_limit="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - 3-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="306"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="445"/>
                    <count group_id="O4" value="224"/>
                    <count group_id="O5" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="54.1" upper_limit="55.9"/>
                    <measurement group_id="O2" value="54.8" lower_limit="53.4" upper_limit="56.2"/>
                    <measurement group_id="O3" value="52.6" lower_limit="51.7" upper_limit="53.5"/>
                    <measurement group_id="O4" value="52.9" lower_limit="51.7" upper_limit="54.1"/>
                    <measurement group_id="O5" value="53.4" lower_limit="51.8" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - 12-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" lower_limit="53.2" upper_limit="55.2"/>
                    <measurement group_id="O2" value="55.2" lower_limit="53.9" upper_limit="56.5"/>
                    <measurement group_id="O3" value="54.1" lower_limit="53.3" upper_limit="54.9"/>
                    <measurement group_id="O4" value="54.0" lower_limit="52.8" upper_limit="55.2"/>
                    <measurement group_id="O5" value="55.6" lower_limit="54.1" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - 24-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="381"/>
                    <count group_id="O4" value="181"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="54.6" upper_limit="56.6"/>
                    <measurement group_id="O2" value="54.7" lower_limit="53.1" upper_limit="56.3"/>
                    <measurement group_id="O3" value="54.1" lower_limit="53.2" upper_limit="55.0"/>
                    <measurement group_id="O4" value="54.1" lower_limit="52.8" upper_limit="55.4"/>
                    <measurement group_id="O5" value="55.8" lower_limit="54.2" upper_limit="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - 36-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="330"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="54.2" upper_limit="56.4"/>
                    <measurement group_id="O2" value="54.5" lower_limit="52.5" upper_limit="56.5"/>
                    <measurement group_id="O3" value="53.9" lower_limit="53.0" upper_limit="54.8"/>
                    <measurement group_id="O4" value="54.2" lower_limit="52.7" upper_limit="55.7"/>
                    <measurement group_id="O5" value="55.4" lower_limit="53.5" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health - 48-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="302"/>
                    <count group_id="O4" value="141"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" lower_limit="53.8" upper_limit="56.0"/>
                    <measurement group_id="O2" value="55.1" lower_limit="53.1" upper_limit="57.1"/>
                    <measurement group_id="O3" value="54.5" lower_limit="53.5" upper_limit="55.5"/>
                    <measurement group_id="O4" value="54.0" lower_limit="52.5" upper_limit="55.5"/>
                    <measurement group_id="O5" value="56.2" lower_limit="54.2" upper_limit="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prostate Cancer Recurrence</title>
        <description>Percentage of patients who had a recurrence of prostate cancer during 5 years of follow-up.</description>
        <time_frame>From date of completion of treatment (radiation or surgery) until the date of recurrence or date of death from any cause, whichever came first, assessed up to 5 years.</time_frame>
        <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Stereotactic Body Radiation Therapy</title>
            <description>Patients who received initial treatment with stereotactic body radiation therapy (SBRT).</description>
          </group>
          <group group_id="O2">
            <title>Radical Prostatectomy</title>
            <description>Patients who received initial treatment with radical prostatectomy.</description>
          </group>
          <group group_id="O3">
            <title>External Body Radiation Therapy</title>
            <description>Patients who received initial treatment with external body radiation therapy (EBRT).</description>
          </group>
          <group group_id="O4">
            <title>Brachytherapy</title>
            <description>Patients who received initial treatment with brachytherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Cancer Recurrence</title>
          <description>Percentage of patients who had a recurrence of prostate cancer during 5 years of follow-up.</description>
          <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="547"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="3.3" upper_limit="13.2"/>
                    <measurement group_id="O2" value="13.5" lower_limit="10.8" upper_limit="16.7"/>
                    <measurement group_id="O3" value="3.6" lower_limit="1.7" upper_limit="6.8"/>
                    <measurement group_id="O4" value="7.2" lower_limit="2.7" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Cancer Anxiety</title>
        <description>Prostate cancer anxiety was measured by the validated Memorial Anxiety Scale for Prostate Cancer (MAX-PC), with 18 questions assessing anxiety related to prostate cancer (11 items, total score 0 to 33), PSA testing (3 items, total score 0 to 9), and fear of recurrence (4 items, total score 0 to 12). The subscale for prostate cancer anxiety asks the patient to report how frequently comments about prostate cancer were true for them during the past week (not at all, rarely, sometimes, or often). The subscale for PSA testing anxiety asks the patient to indicate how frequently situations have ever been true for them. The subscale for anxiety related to prostate cancer recurrence asks the patient to indicate how much they agree or disagree with statements about their own health during the past week. A higher score in each subscale indicates more anxiety.</description>
        <time_frame>4 years</time_frame>
        <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Surveillance</title>
            <description>Patients placed on active surveillance following diagnosis of prostate cancer. Active surveillance was defined with medical records stating this as the plan.</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Body Radiation Therapy</title>
            <description>Patients who received initial treatment with stereotactic body radiation therapy (SBRT).</description>
          </group>
          <group group_id="O3">
            <title>Radical Prostatectomy</title>
            <description>Patients who received initial treatment with radical prostatectomy.</description>
          </group>
          <group group_id="O4">
            <title>External Body Radiation Therapy</title>
            <description>Patients who received initial treatment with external body radiation therapy (EBRT).</description>
          </group>
          <group group_id="O5">
            <title>Brachytherapy</title>
            <description>Patients who received initial treatment with brachytherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Cancer Anxiety</title>
          <description>Prostate cancer anxiety was measured by the validated Memorial Anxiety Scale for Prostate Cancer (MAX-PC), with 18 questions assessing anxiety related to prostate cancer (11 items, total score 0 to 33), PSA testing (3 items, total score 0 to 9), and fear of recurrence (4 items, total score 0 to 12). The subscale for prostate cancer anxiety asks the patient to report how frequently comments about prostate cancer were true for them during the past week (not at all, rarely, sometimes, or often). The subscale for PSA testing anxiety asks the patient to indicate how frequently situations have ever been true for them. The subscale for anxiety related to prostate cancer recurrence asks the patient to indicate how much they agree or disagree with statements about their own health during the past week. A higher score in each subscale indicates more anxiety.</description>
          <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="547"/>
                <count group_id="O4" value="247"/>
                <count group_id="O5" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prostate cancer anxiety - 12-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.5" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.3" upper_limit="1.5"/>
                    <measurement group_id="O3" value="1.6" lower_limit="1.5" upper_limit="1.7"/>
                    <measurement group_id="O4" value="1.6" lower_limit="1.5" upper_limit="1.7"/>
                    <measurement group_id="O5" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate cancer anxiety - 24-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="381"/>
                    <count group_id="O4" value="181"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.2" upper_limit="1.4"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O5" value="1.4" lower_limit="1.3" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate cancer anxiety - 36-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="330"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.3" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.2" upper_limit="1.4"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O5" value="1.3" lower_limit="1.2" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate cancer anxiety - 48-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="302"/>
                    <count group_id="O4" value="141"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.1" upper_limit="1.6"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O5" value="1.3" lower_limit="1.2" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence anxiety - 12-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                    <measurement group_id="O4" value="1.9" lower_limit="1.8" upper_limit="2.0"/>
                    <measurement group_id="O5" value="1.8" lower_limit="1.7" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence anxiety - 24-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="381"/>
                    <count group_id="O4" value="181"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.6" lower_limit="1.5" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                    <measurement group_id="O4" value="1.8" lower_limit="1.7" upper_limit="1.9"/>
                    <measurement group_id="O5" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence anxiety - 36-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="330"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                    <measurement group_id="O4" value="1.9" lower_limit="1.8" upper_limit="2.0"/>
                    <measurement group_id="O5" value="1.6" lower_limit="1.5" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrence anxiety - 48-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="302"/>
                    <count group_id="O4" value="141"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.6" upper_limit="1.8"/>
                    <measurement group_id="O4" value="1.8" lower_limit="1.7" upper_limit="1.9"/>
                    <measurement group_id="O5" value="1.6" lower_limit="1.5" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA test anxiety - 12-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="419"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.0" upper_limit="1.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.2" upper_limit="1.2"/>
                    <measurement group_id="O4" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                    <measurement group_id="O5" value="1.1" lower_limit="1.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA test anxiety - 24-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="381"/>
                    <count group_id="O4" value="181"/>
                    <count group_id="O5" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.0" upper_limit="1.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.2" upper_limit="1.2"/>
                    <measurement group_id="O4" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                    <measurement group_id="O5" value="1.1" lower_limit="1.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA test anxiety - 36-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="330"/>
                    <count group_id="O4" value="145"/>
                    <count group_id="O5" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.0" upper_limit="1.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.2" upper_limit="1.2"/>
                    <measurement group_id="O4" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                    <measurement group_id="O5" value="1.1" lower_limit="1.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA test anxiety - 48-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="190"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="302"/>
                    <count group_id="O4" value="141"/>
                    <count group_id="O5" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="1.1" lower_limit="1.0" upper_limit="1.2"/>
                    <measurement group_id="O3" value="1.2" lower_limit="1.2" upper_limit="1.2"/>
                    <measurement group_id="O4" value="1.2" lower_limit="1.1" upper_limit="1.3"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decisional Regret</title>
        <description>Decisional regret was measured by a validated scale for prostate cancer. The five items of the decisional regret scale assess (on a Likert scale) a patient's feeling that he chose the wrong treatment, a wish to change the decision, or doubt about treatment value.
Answers are converted to a score from 0 (no regret) to 100 (maximum regret). Decisional regret provides an assessment of the overall decisional and treatment experience from a patient perspective.</description>
        <time_frame>4 years</time_frame>
        <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Surveillance</title>
            <description>Patients placed on active surveillance following diagnosis of prostate cancer. Active surveillance was defined with medical records stating this as the plan.</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Body Radiation Therapy</title>
            <description>Patients who received initial treatment with stereotactic body radiation therapy (SBRT).</description>
          </group>
          <group group_id="O3">
            <title>Radical Prostatectomy</title>
            <description>Patients who received initial treatment with radical prostatectomy.</description>
          </group>
          <group group_id="O4">
            <title>External Body Radiation Therapy</title>
            <description>Patients who received initial treatment with external body radiation therapy (EBRT).</description>
          </group>
          <group group_id="O5">
            <title>Brachytherapy</title>
            <description>Patients who received initial treatment with brachytherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Decisional Regret</title>
          <description>Decisional regret was measured by a validated scale for prostate cancer. The five items of the decisional regret scale assess (on a Likert scale) a patient's feeling that he chose the wrong treatment, a wish to change the decision, or doubt about treatment value.
Answers are converted to a score from 0 (no regret) to 100 (maximum regret). Decisional regret provides an assessment of the overall decisional and treatment experience from a patient perspective.</description>
          <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="547"/>
                <count group_id="O4" value="247"/>
                <count group_id="O5" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="406"/>
                    <count group_id="O4" value="193"/>
                    <count group_id="O5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="6.0" upper_limit="13.4"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O3" value="15.0" lower_limit="11.7" upper_limit="18.9"/>
                    <measurement group_id="O4" value="8.3" lower_limit="4.8" upper_limit="13.1"/>
                    <measurement group_id="O5" value="9.7" lower_limit="4.5" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="368"/>
                    <count group_id="O4" value="174"/>
                    <count group_id="O5" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="3.7" upper_limit="10.5"/>
                    <measurement group_id="O2" value="7.6" lower_limit="2.8" upper_limit="15.8"/>
                    <measurement group_id="O3" value="18.8" lower_limit="14.9" upper_limit="23.1"/>
                    <measurement group_id="O4" value="8.6" lower_limit="4.9" upper_limit="13.8"/>
                    <measurement group_id="O5" value="6.5" lower_limit="2.1" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="316"/>
                    <count group_id="O4" value="138"/>
                    <count group_id="O5" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="2.8" upper_limit="9.7"/>
                    <measurement group_id="O2" value="9.5" lower_limit="3.9" upper_limit="18.5"/>
                    <measurement group_id="O3" value="13.9" lower_limit="10.3" upper_limit="18.2"/>
                    <measurement group_id="O4" value="10.1" lower_limit="5.7" upper_limit="16.4"/>
                    <measurement group_id="O5" value="9.5" lower_limit="3.6" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48-months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="292"/>
                    <count group_id="O4" value="136"/>
                    <count group_id="O5" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="3.0" upper_limit="10.3"/>
                    <measurement group_id="O2" value="7.5" lower_limit="2.1" upper_limit="18.2"/>
                    <measurement group_id="O3" value="14.0" lower_limit="10.3" upper_limit="18.6"/>
                    <measurement group_id="O4" value="12.5" lower_limit="7.5" upper_limit="19.3"/>
                    <measurement group_id="O5" value="12.1" lower_limit="5.4" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5-year Mortality</title>
        <description>Percentage of patients who died within 5 years of follow-up.</description>
        <time_frame>From date of diagnosis until date of death or end of follow-up up to 5 years</time_frame>
        <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Surveillance</title>
            <description>Patients placed on active surveillance following diagnosis of prostate cancer. Active surveillance was defined with medical records stating this as the plan.</description>
          </group>
          <group group_id="O2">
            <title>Stereotactic Body Radiation Therapy</title>
            <description>Patients who received initial treatment with stereotactic body radiation therapy (SBRT).</description>
          </group>
          <group group_id="O3">
            <title>Radical Prostatectomy</title>
            <description>Patients who received initial treatment with radical prostatectomy.</description>
          </group>
          <group group_id="O4">
            <title>External Body Radiation Therapy</title>
            <description>Patients who received initial treatment with external body radiation therapy (EBRT).</description>
          </group>
          <group group_id="O5">
            <title>Brachytherapy</title>
            <description>Patients who received initial treatment with brachytherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>5-year Mortality</title>
          <description>Percentage of patients who died within 5 years of follow-up.</description>
          <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="547"/>
                <count group_id="O4" value="247"/>
                <count group_id="O5" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="6.8" upper_limit="12.8"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.6" upper_limit="8.2"/>
                    <measurement group_id="O3" value="3.3" lower_limit="2.0" upper_limit="5.2"/>
                    <measurement group_id="O4" value="11.3" lower_limit="7.7" upper_limit="16.0"/>
                    <measurement group_id="O5" value="4.8" lower_limit="1.8" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Physician Visits During Follow-up</title>
        <description>Number of physician and specialist visits during treatment, subsequent monitoring of recurrence and management of prostate cancer treatment-related morbidity. Assessed through analysis of healthcare claims linked to cohort data.</description>
        <time_frame>4 years</time_frame>
        <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Surveillance</title>
            <description>Patients placed on active surveillance following diagnosis of prostate cancer. Active surveillance was defined with medical records stating this as the plan.</description>
          </group>
          <group group_id="O2">
            <title>Any Active Treatment</title>
            <description>Patients who received initial treatment with surgery or radiation, including brachytherapy or SBRT.</description>
          </group>
          <group group_id="O3">
            <title>Radical Prostatectomy</title>
            <description>Patients who received initial treatment with radical prostatectomy.</description>
          </group>
          <group group_id="O4">
            <title>SBRT/EBRT</title>
            <description>Patients who received initial treatment with stereotactic body radiation therapy (SBRT) or external body radiation therapy (EBRT).</description>
          </group>
          <group group_id="O5">
            <title>Brachytherapy</title>
            <description>Patients who received initial treatment with brachytherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Physician Visits During Follow-up</title>
          <description>Number of physician and specialist visits during treatment, subsequent monitoring of recurrence and management of prostate cancer treatment-related morbidity. Assessed through analysis of healthcare claims linked to cohort data.</description>
          <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
          <units>visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="211"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total prostate cancer visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="3.3"/>
                    <measurement group_id="O2" value="4.6" spread="3.2"/>
                    <measurement group_id="O3" value="4.4" spread="3.4"/>
                    <measurement group_id="O4" value="5.0" spread="3.1"/>
                    <measurement group_id="O5" value="4.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total physician visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="3.8"/>
                    <measurement group_id="O2" value="6.1" spread="3.7"/>
                    <measurement group_id="O3" value="5.6" spread="3.9"/>
                    <measurement group_id="O4" value="6.8" spread="3.6"/>
                    <measurement group_id="O5" value="6.0" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General practitioner visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.4"/>
                    <measurement group_id="O2" value="0.8" spread="1.6"/>
                    <measurement group_id="O3" value="0.6" spread="1.4"/>
                    <measurement group_id="O4" value="1.1" spread="1.7"/>
                    <measurement group_id="O5" value="0.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urology/Oncology visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="3.3"/>
                    <measurement group_id="O2" value="4.1" spread="2.6"/>
                    <measurement group_id="O3" value="4.0" spread="2.9"/>
                    <measurement group_id="O4" value="4.4" spread="2.5"/>
                    <measurement group_id="O5" value="3.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other specialists visits</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.1" spread="0.6"/>
                    <measurement group_id="O3" value="0.1" spread="0.7"/>
                    <measurement group_id="O4" value="0.1" spread="0.5"/>
                    <measurement group_id="O5" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Diagnostic Tests and Procedures During Follow-up</title>
        <description>Number of diagnostic tests and procedures including biopsies, radiographic scans, laboratory tests, and procedures to assess cancer progression (active surveillance) or recurrence and work-up for treatment-related morbidity. Assessed through analysis of healthcare claims linked to cohort data.</description>
        <time_frame>4 years</time_frame>
        <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Surveillance</title>
            <description>Patients placed on active surveillance following diagnosis of prostate cancer. Active surveillance was defined with medical records stating this as the plan.</description>
          </group>
          <group group_id="O2">
            <title>Any Active Treatment</title>
            <description>Patients who received initial treatment with surgery or radiation, including brachytherapy or SBRT.</description>
          </group>
          <group group_id="O3">
            <title>Radical Prostatectomy</title>
            <description>Patients who received initial treatment with radical prostatectomy.</description>
          </group>
          <group group_id="O4">
            <title>SBRT/EBRT</title>
            <description>Patients who received initial treatment with stereotactic body radiation therapy (SBRT) or external body radiation therapy (EBRT).</description>
          </group>
          <group group_id="O5">
            <title>Brachytherapy</title>
            <description>Patients who received initial treatment with brachytherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Diagnostic Tests and Procedures During Follow-up</title>
          <description>Number of diagnostic tests and procedures including biopsies, radiographic scans, laboratory tests, and procedures to assess cancer progression (active surveillance) or recurrence and work-up for treatment-related morbidity. Assessed through analysis of healthcare claims linked to cohort data.</description>
          <population>We analyzed data from NC ProCESS, a population-based, prospective prostate cancer patient cohort. The analytic cohort were men who completed baseline survey info &amp; either underwent active surveillance or received initial treatment with stereotactic body radiation therapy, radical prostatectomy, external beam radiation therapy, or brachytherapy.</population>
          <units>tests or procedures</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="211"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSA test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="2.3"/>
                    <measurement group_id="O2" value="4.7" spread="2.8"/>
                    <measurement group_id="O3" value="5.3" spread="3.2"/>
                    <measurement group_id="O4" value="4.3" spread="2.4"/>
                    <measurement group_id="O5" value="4.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other tests and procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.3"/>
                    <measurement group_id="O2" value="0.4" spread="0.6"/>
                    <measurement group_id="O3" value="0.2" spread="0.5"/>
                    <measurement group_id="O4" value="0.4" spread="0.6"/>
                    <measurement group_id="O5" value="0.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total tests and procedures</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="2.7"/>
                    <measurement group_id="O2" value="5.1" spread="2.9"/>
                    <measurement group_id="O3" value="5.5" spread="3.3"/>
                    <measurement group_id="O4" value="4.7" spread="2.4"/>
                    <measurement group_id="O5" value="4.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>Serious and other (not including serious) adverse events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>NC ProCESS Cohort</title>
          <description>NC ProCESS cohort is a population-based, prospective prostate cancer patient cohort.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1110"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ronald Chen</name_or_title>
      <organization>The University of North Carolina at Chapel Hill</organization>
      <phone>984-974-0400</phone>
      <email>ronald_chen@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

